Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.66 |
| ▸ | PDE4A | P27815 | 6/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6306158 | 0.83 | PPARG (0.68) | PPARG | |
| SCHEMBL6712738 | 0.82 | PPARG (0.81) | PPARG | |
| SCHEMBL5882208 | 0.81 | PPARG (0.75) | PPARG | |
| SCHEMBL5882012 | 0.81 | PPARG (0.64) | PPARGPTGER3 | |
| SCHEMBL6299873 | 0.81 | PPARG (0.64) | PPARG | |
| SCHEMBL6298795 | 0.80 | PPARG (0.64) | PPARG | |
| Atx08-001 SCHEMBL682052 | 0.80 | PPARG (1.00) | PPARG | |
| Atx08-001 SCHEMBL29368164 | 0.80 | PPARG (1.00) | PPARG | |
| Atx08-001 SCHEMBL29691565 | 0.80 | PPARG (1.00) | PPARG | |
| SCHEMBL5881819 | 0.79 | PPARG (0.62) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
| EP-1132087-A1 | REMEDIES FOR POLYCYSTIC OVARY SYNDROME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | PPARG 4239/4885PDE4A 3891/4885PDE4B 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.